Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
about
Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.CYP3A activity: towards dose adaptation to the individual.Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans.Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients.Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.Use of microdose phenotyping to individualise dosing of patients.Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies.Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms.Concentration effect relationship of CYP3A inhibition by ritonavir in humans.Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.Pharmacokinetic interaction of intravenous fentanyl with ketoconazole.Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.Prolonged sedation of lorazepam due to absent UGT2B4/2B7 glucuronidation.Normal CYP3A activity during arsenic trioxide therapy
P2860
Q34635596-E035A222-386A-4ACC-811A-F01E1C2EBEE0Q34810573-629CF1DB-5A47-48B3-A7DF-01DF04D87818Q36072448-26C05505-4F59-4AC0-AC9F-38432D231F45Q36243653-B503FA8D-BC0E-4F98-879B-A8416C1BF453Q36562516-74AD3369-A260-4F10-9130-EBA694DE121EQ37193103-EF46B57E-9F38-458D-8BC4-CF6A9789CEFDQ37492042-99B47E9C-BE7F-4A33-8D5D-617AD6670433Q38763583-2A36C8D1-FAE0-41DE-98E0-CE51CB711CC9Q39798811-40AFBF52-97A4-44C5-AD35-E03BE1C1E951Q40171742-FC35A4C7-7358-4D10-A0BE-C4ABD3BE8988Q40929413-E5A22753-662B-44D9-8AAA-22C78B8A02ACQ40996401-3C17A3A2-C983-42AF-AA66-4D3A8FEF99F7Q42710782-B4A6B2F0-2CCD-494D-830E-1A566582DD6BQ44998438-3DE5DCB1-F6D7-4A1D-A3CE-A9C4962B0CDDQ45718060-35162AF3-C07F-446F-99D1-604B1B8A4366Q45995116-558F2577-AE70-4FA6-A425-41A7A110A269Q47425844-BFCD2044-54A4-4293-BFF1-E451E0F40E3AQ47752672-F81D79B9-3248-4BAF-B25A-03514486C9E0Q47793459-59B3C05F-F356-4737-A7D8-5B0F26967819Q47803945-2E2A7EBF-995A-4E69-B3CD-1D82355C95E3Q48010621-F62AFD01-213B-4F6E-888A-5D6CD6401F16Q48025123-B0F4C3DA-5ED6-4F69-8CDD-DF7B2CE40F84Q48131744-7A418FFD-7838-4637-8C35-D1FAC7CC383EQ48333024-6D863BD5-343C-4BF5-AE68-815691870F05Q51110220-CAB9E615-33A1-4418-B982-1BD8267C5C4FQ54420274-E4763CE8-3F15-4568-84CB-3A909E721816Q56832232-C964B9E8-52D2-4A4B-B4D7-8988FDC8A56C
P2860
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Determining the time course of ...... g A limited sampling strategy.
@en
Determining the time course of ...... g A limited sampling strategy.
@nl
type
label
Determining the time course of ...... g A limited sampling strategy.
@en
Determining the time course of ...... g A limited sampling strategy.
@nl
prefLabel
Determining the time course of ...... g A limited sampling strategy.
@en
Determining the time course of ...... g A limited sampling strategy.
@nl
P2093
P2860
P50
P356
P1476
Determining the time course of ...... g A limited sampling strategy.
@en
P2093
K-D Riedel
S Katzenmaier
P2860
P304
P356
10.1038/CLPT.2011.164
P407
P577
2011-09-21T00:00:00Z